comprehensive -WSS

comprehensive

author：fashion 2025-10-01 04:11:40 - browse：61

This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

Hello, friends! I’m in San Francisco for the STAT Breakthrough Summit. Later today, I’ll be “fireside chatting” with Cytokinetics CEO Robert Blum. It’s not too late to join us virtually. Check out details here.

It’s a travel-shortened week for me, so in this newsletter, I decided to dive deep into PDS Biotech and its experimental drug for head and neck cancer. PDS is what I’d call a biotech cult stock.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Biotech stock slump in 2023: awaiting the turnaround

WSS

A fugitive mob suspect in Greece is betrayed by his passion for hometown Naples soccer champions

Paxlovid rebound happens. Why and to whom are still a mystery

Sweden knocks USA out of World Cup in penalty kicks

Ukraine and a new approach to mental health in war

Second xenotransplant done with gene

Hearing on Medicare drug price negotiation gets unusually heated

explore

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

Cancer drug shortages should be causing more outrage

Hearing on Medicare drug price negotiation gets unusually heated

Supreme Court strikes down use of affirmative action

Doctors push to include dialysis machines in emergency stockpile

After affirmative action ruling, medical educators look to 'holistic review'

How CRISPR works, explained in two minutes

What does generative AI mean for health care? We asked experts

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

Moonlake's readout produced a cash windfall. Risks remain

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

knowledge

Hearing on Medicare drug price negotiation gets unusually heated

With heat waves through August, officials warn of health risks

Lasker Awards 2023: Winners in biomedical research

Election results set back Medicaid expansion plans

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

Readout LOUD podcast: possible new ALS drug, artificial wombs

Wikipedia

entertainment

focus

leisure time